Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-abfb98258fb6ebad664e6e102308dcc0",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-abfb98258fb6ebad664e6e102308dcc0",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-abfb98258fb6ebad664e6e102308dcc0",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-abfb98258fb6ebad664e6e102308dcc0\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-abfb98258fb6ebad664e6e102308dcc0</b></p><a name=\"composition-en-abfb98258fb6ebad664e6e102308dcc0\"> </a><a name=\"hccomposition-en-abfb98258fb6ebad664e6e102308dcc0\"> </a><a name=\"composition-en-abfb98258fb6ebad664e6e102308dcc0-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/439/001 (100 capsules)</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - mycophenolate</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/07/439/001 (100 capsules)"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mpabfb98258fb6ebad664e6e102308dcc0"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - mycophenolate",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Mycophenolate mofetil Teva is and what it is used for</li><li>What you need to know before you take Mycophenolate mofetil Teva</li><li>How to take Mycophenolate mofetil Teva</li><li>Possible side effects</li><li>How to store Mycophenolate mofetil Teva</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What mycophenolate is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What mycophenolate is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Mycophenolate mofetil Teva is a medicine that is used to suppress immune activity.</p><p>The active substance in this medicine is called mycophenolate mofetil.</p><p>Mycophenolate mofetil Teva is used to prevent your body rejecting a transplanted kidney, heart or liver. It is used in combination with other medicines with a similar function (i.e. ciclosporin and corticosteroids).</p></div>"
}
},
{
"title" : "2. What you need to know before you take mycophenolate",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take mycophenolate"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>WARNING Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions. If you do not fully understand these instructions, please ask your doctor to explain them again before you take mycophenolate. See also further information in this section under Warnings and precautions and Pregnancy, contraception and breast-feeding .</p><p>Do not take Mycophenolate mofetil Teva, if you are allergic to mycophenolate mofetil, mycophenolic acid or any of the other ingredients of this medicine (listed in section 6). if you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage. if you are pregnant or planning to become pregnant or think you may be pregnant. if you are not using effective contraception (see Pregnancy, contraception and breast-feeding). if you are breast-feeding. Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Mycophenolate mofetil Teva. Warnings and precautions Talk to your doctor straight away before starting treatment with Mycophenolate mofetil Teva: if you are older than 65 years as you may have an increased risk of developing adverse events such as certain viral infections, gastrointestinal bleeding and pulmonary oedema when compared to younger patients. if you experience any evidence of infection (e.g. fever, sore throat), unexpected bruising and/or bleeding. if you have or ever have had any problems with your digestive system, e.g. stomach ulcers. if you are planning to become pregnant, or if you get pregnant while you or your partner are taking Mycophenolate mofetil Teva. if you have a hereditary enzyme deficiency such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p><p>Mycophenolate mofetil Teva reduces your body s defence mechanism. Because of this, there is an increased risk of skin cancer. Therefore you should limit your exposure to sunlight and ultraviolet (UV) light by wearing appropriate protective clothing and using a sunscreen with a high protection factor.</p><p>You must not donate blood during treatment with Mycophenolate mofetil Teva and for at least 6 weeks after stopping treatment. Men must not donate semen during treatment with Mycophenolate mofetil Teva and for at least 90 days after stopping treatment.</p><p>Children and adolescents Mycophenolate mofetil Teva is used in children and adolescents (aged 2 to 18) to prevent a body rejecting a transplanted kidney. Mycophenolate mofetil Teva should not be used in children and adolescents (aged 2 to 18) for heart or liver transplantation. Mycophenolate mofetil Teva should not be used at all in children under 2 years because based on the limited safety and efficacy data for this age group no dose recommendations can be made.</p><p>Other medicines and Mycophenolate mofetil Teva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>If you answer yes to any of the following questions talk to your doctor before you start to take Mycophenolate mofetil Teva: Are you taking any medicines containing: * azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), * cholestyramine (used to treat patients with high blood cholesterol), * rifampicin (antibiotic), * antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), * phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), * antibiotics (used to treat bacterial infections), * isavuconazole (used to treat fungal infections), * telmisartan (used to treat high blood pressure) * or any other medicines (including those you can buy without a prescription) that your doctor does not know about? Do you need to have a vaccination (live vaccines)? Your doctor will have to advise you what is indicated for you.</p><p>Pregnancy, contraception and breast-feeding</p><p>Contraception in women taking Mycophenolate mofetil Teva If you are a woman who could become pregnant you must use an effective method of contraception with Mycophenolate mofetil Teva. This includes: Before you start taking Mycophenolate mofetil Teva During your entire treatment with Mycophenolate mofetil Teva For 6 weeks after you stop taking Mycophenolate mofetil Teva. Talk to your doctor about the most suitable contraception for you. This will depend on your individual situation. Two forms of contraception are preferable as this will reduce the risk of unintended pregnancy. Contact your doctor as soon as possible, if you think your contraception may not have been effective or if you have forgotten to take your contraceptive pill.</p><p>You cannot become pregnant if any of the following conditions applies to you: You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have treatment for cancer, then there is still a chance you could become pregnant). Your fallopian tubes and both ovaries have been removed by surgery (bilateral salpingo- oophorectomy). Your womb (uterus) has been removed by surgery (hysterectomy). Your ovaries no longer work (premature ovarian failure, which has been confirmed by a specialist gynaecologist). You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner`s syndrome or uterine agenesis. You are a child or teenager who has not started having periods.</p><p>Contraception in men taking Mycophenolate mofetil Teva The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, a risk cannot be completely excluded. As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking Mycophenolate mofetil Teva.</p><p>If you are planning to have a child, talk to your doctor about the potential risks and alternative therapies.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will talk to you about the risks in case of pregnancy and the alternatives you can take to prevent rejection of your transplant organ if: You plan to become pregnant. You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant. You have sex without using effective methods of contraception. If you do become pregnant during the treatment with mycophenolate, you must inform your doctor immediately. However, keep taking Mycophenolate mofetil Teva until you see him or her.</p><p>Pregnancy Mycophenolate causes a very high frequency of miscarriage (50%) and of severe birth defects (23-27%) in the unborn baby. Birth defects which have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed)).Your baby may be affected by one or more of these. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor may request more than one test to ensure you are not pregnant before starting treatment.</p><p>Breast-feeding Do not take Mycophenolate mofetil Teva if you are breast-feeding. This is because small amounts of the medicine can pass into the mother s milk.</p><p>Driving and using machines Mycophenolate mofetil Teva has a moderate influence on your ability to drive or use any tools or machines. If you feel drowsy, numb or confused, talk to your doctor or nurse and do not drive or use any tools or machines until you feel better.</p><p>Mycophenolate mofetil Teva contains sodium This medicine contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take mycophenolate",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take mycophenolate"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your treatment is started and monitored by a doctor who is specialised in transplants.</p><p>The usual way to take Mycophenolate mofetil Teva is as follows:</p><p>Kidney Transplant</p><p>Adults The first dose will be given within 72 hours after the transplant operation. The recommended daily dose is 8 capsules (2 g of the active ingredient) taken as 2 separate doses. This means taking 4 capsules in the morning then 4 capsules in the evening.</p><p>Children and adolescents (aged 2 to 18) The dose given will vary depending on the size of the child. Your doctor will decide the most appropriate dose based on body surface area (height and weight). The recommended dose is 600 mg/m2 taken twice a day.</p><p>Heart Transplant</p><p>Adults The first dose will be given within 5 days following the transplant operation. The recommended daily dose is 12 capsules (3 g of the active ingredient) taken as 2 separate doses. This means taking 6 capsules in the morning then 6 capsules in the evening.</p><p>Children There is no information for the use of Mycophenolate mofetil Teva in children with a heart transplant.</p><p>Liver Transplant</p><p>Adults The first dose of oral Mycophenolate mofetil Teva will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines. The recommended daily dose is 12 capsules (3 g of the active ingredient) taken as 2 separate doses. This means taking 6 capsules in the morning then 6 capsules in the evening.</p><p>Children There is no information for the use of Mycophenolate mofetil Teva in children with a liver transplant.</p><p>Method and route of administration Swallow your capsules whole with a glass of water. You can take them with or without food. Do not break or crush them and do not take any capsules that have broken open or split. Avoid contact with any powder that spills out from damaged capsules. If a capsule breaks open accidentally, wash any powder from your skin with soap and water. If any powder gets into your eyes or mouth, rinse thoroughly with plenty of plain, fresh water.</p><p>Treatment will continue for you as long as you need immunosuppression to prevent rejection of your transplanted organ.</p><p>If you take more Mycophenolate mofetil Teva than you should It is important not to take too many capsules. Contact your nearest hospital Accident and Emergency department or a doctor for advice if you have swallowed more capsules than you have been told to take or if you think a child has swallowed any.</p><p>If you forget to take Mycophenolate mofetil Teva If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Mycophenolate mofetil Teva Do not stop taking Mycophenolate mofetil Teva because you feel better. It is important to take the medicine for as long as the doctor has told you to. Stopping your treatment with Mycophenolate mofetil Teva may increase the chance of rejection of your transplanted organ. Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Talk to a doctor straight away if you notice any of the following serious side effects you may need urgent medical treatment:</p><ul><li>you have a sign of infection such as a fever or sore throat.</li><li>you have any unexpected bruising or bleeding.</li><li>you have a rash, swelling of your face, lips, tongue or throat, with difficulty breathing - you may be having a serious allergic reaction to the medicine (such as anaphylaxis, angioeodema).</li><li>you have black or bloody stool or if you vomit blood or dark particles that look like coffee grounds. These may be signs of bleeding in the stomach or intestines.</li></ul><p>The frequency of certain side effects is dependent on the transplanted organ, i.e. some side effects can occur more or less often depending on whether this medicinal product is being taken to prevent your body from rejecting a transplanted heart or a transplanted kidney. For the sake of clarity each side effect is always listed under its highest frequency.</p><p>Other side effects</p><p>Very common (may affect more than 1 in 10 people) bacterial, viral and/or fungal infections serious infection which may affect the whole body decrease in the number of white blood cells, platelets or red blood cells, which can result in increased risk of infections, bruising, bleeding, breathlessness and weakness bleeding underneath the skin increase in the number of white blood cells too much acid in the body high level of cholesterol and/or lipids in the blood high level of sugar in the blood high level of potassium in the blood, low level of potassium, magnesium, calcium and/or phosphate in the blood high level of uric acid in the blood, gout feeling restless, abnormalities of thought, perception and levels of awareness, depression, feeling anxious, difficulty in sleeping increased tension of the muscles, shaking, sleepiness, feeling dizzy, headache, tingling, pricking or numbness faster heart beat low/high blood pressure, widening of blood vessels accumulation of fluid in the lung, shortness of breath, cough bloated belly vomiting, stomach pain, diarrhoea, feeling sick constipation, indigestion, wind (flatulence) decreased appetite changes in different laboratory parameters inflammation of the liver, yellowing of the skin and whites of the eyes growth of the skin, rash, acne muscle weakness joint pain kidney problems blood in the urine fever, feeling of coldness, pain, feeling weak and feeble fluid retention in the body part of an internal organ or tissue bulging through a weak spot in the abdominal muscles muscle pain, neck and back pain</p><p>Common (may affect up to 1 in 10 people) skin cancer, non-cancerous growth of the skin abnormal and excessive growth of tissue decrease in the number of all blood cells benign enlargement of the lymph nodes, inflammatory changes of the skin (pseudolymphoma) decreased weight abnormal thinking fit distortion of the sense of taste blood clot that forms within a vein inflammation of the tissue that lines the inner wall of the abdomen and covers most of the abdominal organs bowel blockage inflammation of the colon which causes abdominal pain or diarrhoea (sometimes caused by cytomegalovirus), ulcer of the mouth and/or stomach and/or duodenum, inflammation of the stomach, oesophagus and/or mouth and lips belching hair loss feeling unwell overgrowth of the gum tissue inflammation of the pancreas, which causes severe pain in the abdomen and back</p><p>Uncommon (may affect up to 1 in 100 people) protozoal infections proliferation of the lymphatic tissue, including malignant tumours insufficient production of red blood cells serious diseases of the bone marrow accumulation of lymphatic fluid within the body shortness of breath, cough, which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung). Talk to your doctor if you develop a persistent cough or breathlessness. decrease in the amount of antibodies in the blood severe reduction in the number of certain white blood cells (possible symptoms are fever, sore throat, frequent infections) (agranulocytosis)</p><p>Not known (frequency cannot be estimated from the available data) alterations of the inner wall of the small intestine (intestinal villous atrophy) serious inflammation of the membrane that covers the brain and spinal cord serious inflammation of the heart and its valves bacterial infections usually resulting in a serious lung disorder (tuberculosis, atypical mycobacterial infection) serious disease of the kidney (BK virus associated nephropathy) serious disease of the central nervous system (JC virus associated progressive multifocal leucoencephalopathy) decrease in the number of certain white blood cells (neutropenia) change of the shape of certain white blood cells</p><p>Do not stop taking your medicine unless you have discussed this with your doctor first.</p><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store mycophenolate",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store mycophenolate"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines no longer required. These measures will help to protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Mycophenolate mofetil Teva contains</p><p>The active substance is mycophenolate mofetil. Each capsule contains 250 mg mycophenolate mofetil. The other ingredients are: Capsule content Pregelatinised maize starch Povidone K-Croscarmellose sodium Magnesium stearate Capsule shells Cap Indigo carmine (E132) Titanium dioxide (E171) Gelatin Body Red iron oxide (E172) Yellow iron oxide (E172) Titanium dioxide (E171) Gelatin Black ink containing: shellac, black iron oxide (E172), propylene glycol and potassium hydroxide</p><p>What Mycophenolate mofetil Teva looks like and contents of the pack</p><p>Hard capsules Body: caramel opaque, printed 250 axially in black ink. Cap: light blue opaque printed M axially in black ink.</p><p>Mycophenolate mofetil Teva 250 mg hard capsules are available in PVC/PVdC-aluminium blisters in pack sizes of 100 or 300 or 100 x 1 capsules per carton.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorisation Holder Teva B.V. Swensweg 5 2031GA Haarlem Netherlands</p><p>Manufacturers Teva Pharmaceutical Works Private Limited Company Pallagi t 13. Debrecen H-4Hungary</p><p>Pharmachemie B.V. Swensweg 5 2031 GA Haarlem The Netherlands</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG T l/Tel: +32 38207Lietuva UAB Teva Baltics Tel: +370 52660</p><p>: +359 24899Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien T l/Tel: +32 38207 esk republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007Magyarorsz g Teva Gy gyszergy r Zrt. Tel: +36 12886Danmark Teva Denmark A/S Tlf: +45 44985Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 2075407Deutschland TEVA GmbH Tel: +49 73140Nederland Teva Nederland B.V. Tel: +31 8000228Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610Norge Teva Norway AS Tlf: +47 66775<br/>Specifar . . . . : +30 2118805 sterreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970Espa a Teva Pharma, S.L.U. Tel: +34 913873Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459France Teva Sant<br/>T l: +33 155917Portugal Teva Pharma - Produtos Farmac uticos, Lda. Tel: +351 214767Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720Rom nia Teva Pharmaceuticals S.R.L. Tel: +40 212306Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890 sland Teva Pharma Iceland ehf. S mi: +354 5503Slovensk republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267Italia Teva Italia S.r.l. Tel: +39 028917Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805<br/>Specifar . . . .</p><p>: +30 2118805Sverige Teva Sweden AB Tel: +46 42121Latvija UAB Teva Baltics fili le Latvij<br/>Tel: +371 67323United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407This leaflet was last revised in {MM/YYYY}.</p><p>Detailed information on this medicine is available on the website of the European Medicines Agency</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mpabfb98258fb6ebad664e6e102308dcc0",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mpabfb98258fb6ebad664e6e102308dcc0",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpabfb98258fb6ebad664e6e102308dcc0\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpabfb98258fb6ebad664e6e102308dcc0</b></p><a name=\"mpabfb98258fb6ebad664e6e102308dcc0\"> </a><a name=\"hcmpabfb98258fb6ebad664e6e102308dcc0\"> </a><a name=\"mpabfb98258fb6ebad664e6e102308dcc0-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/439/001 (100 capsules)</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Mycophenolate mofetil Teva 250 mg hard capsules</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/07/439/001 (100 capsules)"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Mycophenolate mofetil Teva 250 mg hard capsules",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
